

Propranolol application in gynecological disease: review

Salwa Samir Anter

MD obstetric gynecology Cairo University, Egypt

Abstract:

Propranolol is β -adrenergic receptor blocker with reported antioxidant effect and anti-inflammatory action, is used in treatment of the hypertension mainly, and main benefit in treatment patients with angina pectoris or myocardial infarction, add to role in central nervous system diseases as migraines and anxiety disorders, and tremor but rarely used in gynecology field in spite of many action either by beta receptor block or other mechanisms it acts with, such as anti-inflammatory, anticancer, antioxidant activity, pro-apoptosis, and wound healing. In this review, we have discussed the various aspects of propranolol that can be applied in clinical gynecology in number of ways such as local contraceptive, in the treatment of Vulvovaginitis by affected main criteria of Trichomonas and Giardia lamblia, which is motility, propranolol inhibited motility of both organism and consequence inhibition of the growth of both organism, for the treatment of genital hemangioma. We have also shed some light on experimental studies – such as its effect on polycystic ovary and endometriosis.

Introduction:

Propranolol is a drug with beta blocker effect and used clinical in treated hypertension Thyrotoxicosis, and recent in capillary hemangiomas, anxiety, and essential tremors.(1) but clinical applications in gynecology is limited and route of administration oral route, injection but

what about vagina route is used only as spermicidal effect

Biography:

Salwa Samir Anter, he is working as a professor at obstetric gynecology Cairo University, Egypt

Publication of speakers:

1. Bryson, Peter D. (1997). Comprehensive review in toxicology for emergency clinicians (3 Ed.). Washington, DC: Taylor & Francis. p. 167. ISBN 9781560326120.
2. Sonia Maccari, Maria Buoncervello, [...], and Giuseppe Marano, Biphasic effects of propranolol on tumor growth in B16F10 melanoma-bearing mice
3. 3_Priviero FB1, Teixeira CE, Claudino MA, De Nucci G, Zanesco A, Antunes E., Vascular effects of long-term propranolol administration after chronic nitric oxide blockade Eur Pharmacology. 2007 Oct 1; 571(2-3):189-96. Pub 2007 Jun 13
4. Giavazzi R1, Sennino B, Coltrini D, Garofalo A, Dossi R, Ronca R, Tosatti MP, Presta M. Distinct role of fibroblast growth factor-2 and vascular endothelial growth factor on tumor growth and angiogenesis. Am J Pathol. 2003 Jun; 162(6):1913-26
5. Stiles J, Amaya C, Pham R, et al. Propranolol treatment of infantile hemangioma endothelial cells: a molecular analysis. Exp Ther Med. 2012; 4:594604.